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Objective: Myeloperoxidase (MPO) has emerged as an important pathophysiological determinant of
inﬂammatory vascular artery disease. It is appreciated that vessel immobilized, rather than circulating,
MPO is critical for the progression of atherosclerotic lesions. The objective of this study was to investigate
whether vessel-immobilized MPO is associated with the extent of coronary plaque burden.
Methods: MPO plasma levels were determined by ELISA before and after heparin-release of vessel-bound
MPO, to study the relation between vascular MPO deposition and densitometrically assessed coronary
plaque burden in 77 patients with stable coronary artery disease.
Results: Patients with a low increase in MPO plasma levels upon heparinization had a signiﬁcantly
smaller total plaque area and volume (12.1[IR:6.2e19.4]mm2 vs. 19.8[IR:11.3e31.5]mm2, p < 0.01; 27.8
[IR:12.3e44.8]mm3 vs. 55.2[IR:24.2e87.5]mm3, p < 0.05). Multivariable linear regression revealed that
DMPO was independently associated with plaque area, and that DMPO increased with the number of
affected vessels. Selective sampling conﬁrmed the predominant role of coronary MPO deposition.
Conclusion: Our data demonstrate that heparin-induced mobilization of vessel-bound MPO is closely
linked to coronary plaque burden and thus further corroborate the evidence for the intimate involve-
ment of this enzyme in vascular pathophysiology, as well as the importance of inﬂammation in
atherosclerosis.
 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.Myeloperoxidase (MPO), a heme-enzyme abundantly expressed
in polymorphonuclear neutrophils (PMN), is critically linked to all
stages of arteriosclerotic disease [1]. MPO oxidizes vascular nitric
oxide (NO, thereby deteriorating endothelial function) [2] and
propagates arteriosclerotic plaque progression through its capacity
to generate various reactive species [3]. Thus, MPO oxidizes low-
density lipoprotein (LDL), thereby leading to enhanced foam cell
formation [4]; and high-density lipoprotein (HDL), converting it to
a dysfunctional and proatherogenic form [5]. MPO negatively in-
ﬂuences eNOS expression and activity [6] and generates 3-nitro-f Cologne, Kerpener Str. 62,
x: þ49 221 47832400.
udolph).
r Ireland Ltd. Open access under CC Btyrosine, a hallmark of oxidative tissue injury [7]. In addition, MPO
elicits cytokine-like properties which are independent of its cata-
lytic activity, in that it activates PMN via CD11b/CD18 integrin [8].
Given its ability to activate matrix degrading metalloproteinases
[9,10], MPO seems to be involved in plaque rupture [11].
After release from activated PMN, the cationic protein MPO
accumulates in the subendothelial layer due to electrostatic in-
teractions with the anionic glycocalyx and extracellular matrix
[7,12]. Administration of heparin, which is strongly anionic, releases
MPO from the vessel wall. In a previous study, our groupwas able to
demonstrate that patients with stable coronary artery disease
(CAD) had a higher degree of MPO liberation, reﬂecting increased
systemic vascular deposition of MPO in CAD. Reversal of vascular
immobilized MPO in vivo translated into improved ﬂow-mediated
dilation, a surrogate for endothelial NO-bioavailability [13].
The current study further extends these results and investigates
whether vascular MPO deposition is indicative of the extent ofY-NC-SA license.
Table 1
Patient baseline characteristics.
DMPO < 533 pM
(n ¼ 20)
DMPO  533 pM
(n ¼ 57)
p
Age, y 68.1  8.9 66.9  10.3 0.66
Gender, female 4 (20.0) 12 (21.1) 0.59
BMI 26.2  3.3 26.7  3.7 0.64
Hypertension 19 (95.0) 52 (91.2) 0.59
Hypercholesterolemia 13 (65.0) 39 (68.4) 0.78
Diabetes 3 (15.0) 15 (26.3) 0.30
Smoking 6 (30.0) 12 (21.1) 0.42
NT-proBNP, pg/ml 152.6  174.1 200.7  234.5 0.43
hs-CRP, mg/dl 2.8  3.7 4.3  6.2 0.36
Leukocyte count, 10e6/
ml
7.5  2.3 7.2  1.3 0.60
LDL, mg/dl 124.6  46.3 110.1  41.0 0.29
ACE-I, ARB 14 (70.0) 37 (64.9) 0.68
Betablocker 13 (65.0) 41 (71.9) 0.56
Statin 13 (65.0) 39 (68.4) 0.78
BMI: body mass index, hs-CRP: high sensitive C-reactive protein, LDL: low density
lipoprotein, NT-pro BNP: N-terminal pro brain natriuretic peptide, ACE-I: angio-
tensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker.
Values are given as mean  standard deviation or frequency (percentage).
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the coronary circulation is the predominant site of MPO deposition.
Accordingly, MPO liberation upon heparinization was assessed in
patients undergoing elective coronary angiography, allowing sub-
sequent measurement of the extent of the angiographically
detectable coronary plaque burden.1. Methods
A detailed methods section is provided in the Online
Supplement. Brieﬂy, patients with stable CAD undergoing elective
coronary angiography who showed at least one coronary stenosis
with a narrowing of >25% of the lumen diameter were consecu-
tively included. Venous blood samples were taken before and
15 min after heparinization (5000 U), where peak MPO plasma
levels are observed after heparin administration [14]. Evaluation of
plaque morphology was determined off-line using QUANTCOR QCA
analysis software (Siemens, Erlangen, Germany) [15]. MPO plasma
levels were assessed by CardioMPO Elisa (Cleveland HeartLab.
Cleveland, OH, USA). To determine the main site of MPO release,
blood samples were collected from the aorta, the coronary sinus
and the femoral vein in a separate group of six patients at one, three
and 5 min following heparin administration. To assess dose de-
pendency of the heparin effect, collagen was incubated with MPO
and increasing doses of heparin, and MPO activity was assessed. A
detailed description of statistical analysis can be found in the
Online Supplement.2. Results
77 consecutive patients (mean age: 66.4  12.6 y; 16% female)
were included. 15 patients (19.5%) exhibited a 1-vessel, 33 (42.9%) a
2-vessel and 29 (37.7%) a 3-vessel disease (average stenosis:
58.9  17.3%). The median MPO plasma levels were 449[IR:314e
876]pM before heparin administration (MPOpre), 1468[IR:1036e
1915]pM after heparin administration (MPOpost). The mean in-
crease in MPO plasma levels (DMPO) was 904.8  698.2 pM. No
correlation was observed between baseline MPO levels and DMPO
(0.176, p ¼ 0.125). No signiﬁcant differences in baseline charac-
teristics were observed between patients within the lowest quartile
of DMPO and those within the other quartiles (Table 1).The total plaque burden expressed as area (PAtotal) and volume
(PVtotal) was signiﬁcantly higher in patients with high DMPO (19.8
[IR:11.3e31.5] vs. 12.1[IR:6.2e19.4]mm2, p < 0.01; 55.2[IR:24.2e
87.5] vs. 27.8[IR:12.3e44.8]mm3, p < 0.05). Overall, DMPO showed
a signiﬁcant correlation with PAtotal (r ¼ 0.24; p < 0.05) and PVtotal
(r ¼ 0.29; p < 0.05; Fig. 1). Similar differences between patients
with high and low DMPO were observed for maximal plaque area
(PAmax) and volume (10.3[IR:6.3e17.6] vs. 6.9[IR:4.9e9.2]mm2,
p < 0.05; 29.9[IR:16.0e51.0] vs. 18.1[IR:10.0e23.8]mm3, p < 0.01;
Fig. 1). Signiﬁcant difference between quartiles was observed
(p < 0.05), with levels of PAtotal and PVtotal increasing with DMPO
quartiles (r ¼ 0.29, p < 0.05; r ¼ 0.30, p < 0.01). Post-hoc analysis
revealed a signiﬁcant difference between each of the three highest
quartiles and the lowest quartile. However, no signiﬁcant difference
was observed between any of the highest three quartiles (Fig. 1).
Separation of the single quartiles revealed signiﬁcant differences
between quartiles for PVmax (p < 0.05), with a trend towards dif-
ferences between PAmax (p ¼ 0.11).
Multivariable linear regression revealed that even after multi-
variate adjustment, DMPO remained independently associated
with PAtotal; with 12.4% of the variation in PAtotal being explainable
by DMPO (partial h2: 0.124; p < 0.013).
No difference between patients with low and high MPOpre or
low and high MPOpost with regard to PAtotal, PVtotal, PAmax, and
PVmax was observed, nor was there a correlation of MPOpre or
MPOpost with any of these parameters.
Elevated DMPO was associated with increasing number of
affected coronaries (1-vessel: 384.2  681.8pM; 2-vessels:
903.2  469.6pM; 3-vessels: 1175.9  785.8pM, p < 0.01; Fig. 2).
DMPO correlated with the number of affected vessels (r ¼ 0.34,
p < 0.01).
A signiﬁcant increase for MPOpost was observed with the in-
crease of affected vessels (1-vessel: 1203[IR:804e1517]pM; 2-
vessels: 1471[950e1841]pM; 3-vessels: 1658[IR:1125e2455]pM;
p < 0.05). In contrast to MPOpre, MPOpost correlated with the
number of vessels affected (r ¼ 0.29; p < 0.01). There was no dif-
ference in degree of coronary calciﬁcation between patients with
low and high DMPO (c2: 2.63, p ¼ 0.45).
In vitro administration of heparin showed a dose-dependent
release of MPO from collagen (fold increase of MPO activity after
20 min incubation with 0.5, 1.0, 2.5 and 10 U/ml of heparin: 5-fold,
5.3-fold, 6.2-fold and 7.2-fold).
In the 6 separate patients from whom blood samples were
collected in the aorta, the coronary sinus and the femoral vein,
heparin administration resulted in a more rapid increase of MPO
plasma levels in aortic and coronary sinus blood compared to
venous blood, indicating a predominant role of MPO deposition in
the coronary circulation in CAD patients (Fig. 2). After 5 min,
equally elevated MPO plasma levels were observed at all collection
sites. No increase in elastase plasma levels was observed, excluding
PMN activation.
3. Discussion
In this study we demonstrate that: 1) patients with a high de-
gree of heparin-induced mobilization of vessel-bound MPO exhibit
a higher angiographically detectable coronary plaque burden, and
2) heparin-induced mobilization of vessel-bound MPO increases
with the number of coronary arteries affected.
MPO has emerged as a powerful predictor of cardiovascular
outcome in patients with acute coronary syndromes [16e18], heart
failure [19], peripheral artery disease [20] and carotid artery disease
[21]. However, conﬂicting results exist concerning the role of MPO
plasma levels in stable CAD [22,23]. A possible confounding factor
might be the vascular deposition of MPO.
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Fig. 2. A) Increase in heparin-induced release of vessel-bound MPO as a surrogate parameter of vascular MPO deposition with increasing number of affected coronary arteries.
ANOVA showed a signiﬁcant difference between the three groups (p< 0.01). Tukey HSD test was used post-hoc to test for differences between single groups. *p< 0.05; **p < 0.01. B)
Change of MPO and elastase plasma levels before (pre) as well as 1, 3 and 5 min after systemic heparin administration in coronary sinus (white bars), venous (gray bars) and aortic
blood samples (black bars). A more rapid increase of MPO plasma levels was observed in coronary sinus compared to venous blood samples. After 5 min MPO plasma levels were
equal at all collection sites. *p < 0.05 vs. pre; #p < 0.05 vs. coronary sinus. C) Plasma elastase levels did not differ following heparin administration.
T.K. Rudolph et al. / Atherosclerosis 231 (2013) 354e358 357Following its release from PMN, MPO is mainly immobilized in
the vessel wall [7,12,24] where MPO exerts its various (patho)bio-
logical effects. A signiﬁcant transcoronary reduction of MPO con-
tent in PMN in patients with unstable CAD has been observed [25].
Using percutaneous coronary intervention as a model of vessel
injury, we were able to demonstrate that MPO plasma levels
showed a transcoronary decrease rather than a transcoronary in-
crease as onemight expect to follow PMN activation [14], indicating
that MPO is indeed immobilized in the coronary vascular wall.
Further evidence in support of this tenet arises from a recent study
demonstrating an intimate interplay between vascular MPO
sequestration and coronary vasomotion [26].
Neutrophil activation occurs not only in unstable but also stable
CAD [27,28]. It therefore appears reasonable that vascular MPO
deposition might function as a “memory” of the PMN activation
state.
The current study extends previous reports on the interrelation
between vascular MPO deposition and functional impairment of
systemic vasomotion [13], by demonstrating a tight correlationFig. 1. Plaque area (PAtotal) and plaque volume (PVtotal) according to vascular MPO depositio
(DMPO < 533 pM) exhibited a signiﬁcantly reduced total plaque area in comparison to th
observed for total plaque volume. PAtotal and PVtotal are the sum of all densitometrically asses
in the lowest quartile of heparin-induced increase MPO plasma levels (DMPO). D) Similarly, P
between groups were assessed by MannWhitney U test. *p < 0.05; **p < 0.01. E, F) Total plaq
between quartiles was revealed by KruskaleWallis test (p < 0.05): PAtotal and PVtotal inc
Spearman’s rho: 0.30, p < 0.01 for PVtotal). Post-hoc analysis demonstrated a signiﬁcant di
remained signiﬁcant after Bonferroni adjustment. No difference was observed between anybetween MPO deposition and structural alterations in the coronary
circulation.
Our data depict a tight association between vascular MPO
deposition and coronary plaque burden. Multivariable linear
regression revealed that plaque burden and vascular MPO deposi-
tion were independently associated after adjustment for a series of
potential confounding factors, such as MPO plasma levels before
heparin administration, NT-pro BNP and hsCRP plasma levels, age,
gender, BMI, hypertension, hyperlipidemia and diabetes. These
ﬁndings further advocate for a potential causal interrelation be-
tween MPO and coronary plaque formation. Moreover, vascular
MPO deposition increased with the number of affected coronaries.
These results are remarkable, since heparinization mobilizes MPO
from the entire vascular bed and not exclusively from the coronary
circulation. As coronary artery disease has been shown to be
accompanied by systemic vascular inﬂammation and also by sys-
temic activation of PMN [29], our data thus support the concept of
the “vulnerable patient”. On the other hand, the more rapid in-
crease of MPO levels in coronary sinus blood compared to venousn. A) Patients in the lowest quartile of heparin-induced increase in MPO plasma levels
ose in the higher quartiles. B) This difference between low and high DMPO was also
sed plaque areas and volumes, respectively. C) PAmax was signiﬁcantly lower in patients
Vmax was observed to be lower in patients in the lowest quartile of DMPO. Differences
ue area and total plaque volume according to quartiles of DMPO. A signiﬁcant difference
reased with increasing DMPO quartiles (Spearman’s rho: 0.29, p < 0.05 for PAtotal;
fference between each of the three highest quartiles and the lowest quartiles, which
of the highest three quartiles. *p < 0.05.
T.K. Rudolph et al. / Atherosclerosis 231 (2013) 354e358358blood presented herein clearly advocates a predominant role
of coronary vascular MPO deposition for the heparin-induced in-
crease in MPO plasma levels in CAD patients; although, clearly, it
can not be ruled out that an increased extracoronary vascular
deposition of MPO in patients with more severe CAD contributed to
the increased MPO levels after heparin administration observed in
these patients.
It is important to note that the results of this study are based on
a small sample size.
In conclusion, our study demonstrates that vascular MPO
deposition is closely linked to the overall coronary plaque burden in
patients with stable CAD, thus strengthening the pathophysiolog-
ical role of MPO in coronary artery disease.
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